373 results about "Nasal congestion" patented technology

The present invention discloses a method of treating nasal congestion and/or relieving sinusitis symptoms in a patient comprising attaching a vibration generating means to the patient head, at a location adjacent to sinuses to be treated, generating a vibration by said vibration generating means, and delivering the same to said patient. The present invention also discloses a device for treating nasal congestion and/or relieving sinusitis symptoms in a patient, comprising attaching means and a vibration generating means; said attaching means are in communication with the patient's head in a location adjacent to said nasal cavity, nasal passageway or sinuses to be treated; said generating means are adapted to vibrate said attaching means, to vibrate the location adjacent to said nasal cavity or sinuses and thus improved mucociliary clearance of secretions in nasal cavity or sinuses.

The present invention relates generally to the field of treatments for nasal congestion, and in particular, to a method and apparatus for alleviating nasal congestion in a patient by mechanically stimulating the sneezing reflex in the patient to urge drainage of the nasal passageways. The method includes inserting an instrument having a work tip portion provided with at least one filament into the nostril of the patient. The nasal mucosa of the patient is then probed with the at least one filament to stimulate in the patient the sneeze reflex. This probing action causes the patient to sneeze. With the patient's mouth closed, the sneeze urges at least one of mucus, fluid and debris in the nasal passages of the patient to be forcibly expelled through the nostrils of the patient thereby draining the nasal cavity of the patient. The instrument used in the performance of this method includes a handle portion upon which the work tip portion is carried. The handle portion may be integrally formed with the work tip portion or releasably attachable thereto. The instrument is further provided with a physical stop associated with one of the work tip portion and the handle portion to prevent injury resulting from the working tip portion being inserted too deeply into the nasal passages of the patient.

A nasal breathing assist device includes one or two open-ended tubular elements each extending along a central tube axis between a relatively large first end and a relatively small second end, and at least one non-resilient tab extends from the first end toward the second end of the tubular element. In embodiments with two tubular elements, a coupler element extends between the first ends of the tubular elements. Each tubular element may further include a liner-shaped filter having a liner portion extending along a central axis between a relatively large end and a relatively small end, and a filter medium spanning at least one of the relatively large end and the relatively small end. The filter is adapted to snap-fit in the tubular element. The tubular element may further include at least one stiffening element affixed to the tubular element.

The present invention relates to a novel nasal formulation for the treatment and prophylaxis of nasal congestion. When an infant is born, its nasal passages are relatively sterile, in time the nasal passages are colonized by fungi, molds and other organisms which compromise the integrity of the nasal and paranasal mucosa. The presence of these organisms elicits a mild chronic inflammatory reaction of the nasal and paranasal mucosa, in some cases leading to congestion and excess production of mucus. This chronic inflammatory process compromises the integrity of the nasal and paranasal mucosa, making it more vulnerable to binding with allergens and other invading organisms such as the rhinovirus. The purpose of this invention is to establish a treatment and prophylaxis of nasal congestion, which will control the presence of the invading organisms in the nasal and paranasal mucosa, reducing congestion as well as mucus production. By reducing the mild chronic inflammation in the nasal passages, prophylaxis with this nasal formulation passively reestablishes the integrity of the nasal and paranasal mucosa, thereby reinforcing the body's defenses against the implantation of allergens and of organisms such as the rhinovirus.

A chemical composition and method for treatment of the common cold, sinusitis and other conditions associated with nasal congestion is provided. The chemical composition is made of predetermined concentrations of thymol, alcohol, eucalyptol, menthol, methyl salicylate, a preservative, saline solution and a buffer. The method includes the step of administering the chemical composition of the invention via either intranasal instillation, oral inhalation or intermittent positive pressure breathing. Administration of the chemical composition via the method of the invention clears the nasal passages and alleviates the symptoms of the common cold, sinusitis, and related conditions.

The present invention relates to a nasal spray containing sodium pyruvate and a preparation method thereof, belonging to the field of medical technology, being characterized in that: the nasal spray containing sodium pyruvate comprises the following components: sodium pyruvate, pyruvic acid, an isoosmotic adjusting agent, a preservative and water. Because the sodium pyruvate is capable of alleviating nasal obstruction and inflammation caused by rhinitis, a medical fluid provided in the invention can be made into a nasal spray medical fluid which is capable of entering nasal cavities by adopting a portable spraying device. The nasal spray medical fluid is particularly suitable for cleaning and removing harmful pollutants in nasal passages, paranasal sinuses and mucosal cilia and is capable of being used in nursing after a nasal cavity operation, relieving rhinostegnosis and reducing respiratory tract irritation and risks of infection. By adding the pyruvic acid to form a buffer solution, tingling caused by using the flushing fluid to wash the cavities can be reduced, and inflammation is alleviated. Allergic symptoms can be prevented or gradually alleviated for the people of special professional who often use the product provided in the invention to wash and care nasal cavities.

The optimum concentration of salt in solutions to combat congestion of the mucosa is a relatively narrow range. This use of in hypertonic saline solutions for treatment of congestion of the mucosa having a concentration within the range of 2.3% to and including 2.7% w/v sodium chloride/water with the most preferred concentration being 2.4% to and including 2.6% w/v of sodium chloride in water brings maximum relief of congestion and for cleansing membranes without causing irritation or discomfort.

Pharmaceutical compositions for the treatment of nasal congestion, wherein the pharmaceutical compositions comprise low concentrations of a super-selective subclass of selective α-2 adrenergic receptor agonists. Methods of using the compositions for the treatment of nasal congestion, cerebrovascular disease or systemic conditions, and as delivery vehicles to deliver other active agents to treat systemic or cerebrovascular diseases or conditions.

The present invention relates to a novel nasal formulation for nasal hygiene and to improve nasal airflow of people suffering from nasal congestion.

Disclosed are an apparatus and related methods for facilitating nasal congested respiration.

A nasal insert may include a wall in the shape of a tube, the wall including a first end defining a first orifice and a second end defining a second orifice. The first end may have a diameter, diagonal measurement, or cross-sectional area larger than that of the second end. The first end may define at least one break in the wall, so that the first end incompletely encircles the first orifice. Thesecond end may completely encircle the second orifice.

The present disclosure describes pharmaceutical compositions and methods for reducing duration, intensity, and/or bothersomeness of common colds in humans and for reducing severity or duration of common cold symptoms such as nasal congestion, runny nose, watery eyes, dry/scratchy throat and sneezing in humans exhibiting such symptoms. The compositions herein comprise extracts of at least one of Luffa Operculata (L. operculata), S. officinale (V. sabadilla), and Galphimia Glauca (G. glauca) in a pharmaceutically acceptable carrier, and in various embodiments, comprise a mixture of all three Luffa Operculata (L. operculata) 10% extract MT, S. officinale (V. sabadilla) 3× extract, and Galphimia Glauca (G. glauca) 10% extract MT in a pharmaceutically acceptable carrier.

The invention provides compositions and methods for treating nasal congestion through ophthalmic delivery. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine.

A pharmaceutical formulation of therapeutically effective amounts of acetaminophen, ibuprofen, and a sympathomimetic drug, such as pseudoephedrine (or its prodrug), or phenylephrine used in the treatment of cold and flu-like symptoms. Such symptoms may include fever, pain, nasal congestion, sinus congestion, runny nose, sore throat, myalgia, ear pressure and fullness, and headache. The formulation further includes various excipients used in the formulation process.

The invention discloses a traditional Chinese medicine preparation for treating cough and a preparation method thereof. The traditional Chinese medicine preparation consists of the following twelve Chinese herbal medicines: ephedra, radix stemonae, negundo chastetree fruit, affine cudweed, loquat seed dried powder, bezoar, radix polygonati officinalis, momordica grosvenori, radix puerariae, herb of savatier monochasma, manglietia fordiana and fig. The preparation method comprises the following steps: uniformly mixing a thick paste and dextrin of the medicine, taking ethanol as a wetting agent to prepare wet granules, drying, cooling, spraying volatile oil, and uniformly mixing, thereby obtaining the traditional Chinese medicine preparation. The preparation has good curative effects on symptoms such as cough, coughing up phlegm, fever with aversion to cold, headache without sweat, body ache and severe nasal obstruction caused by moderate and medium exogenous cold and unsmooth lung qi. Compared with the other process technologies, the medicine is simple and clear in composition and process, and the quality is easily controlled.

A process for preparing Chinese medicine "Biyanling capsule" for treating chronic nasosinusitis, rhinitis, nasal congestion, etc includes such steps as extracting from xanthium fruit by alcohol, decocting dregs, concentrating, drying, extracting volatile oil of magnolia flower and asarum herb, pulverizing 4 Chinese-medicinal materials including scutellaria root, mixing, granulating, adding menthol and additive, mixing all together, and loading in capsules. Its advantage is high curative effect and safety.

A nasal rinse additive composition includes oleoresin capsicum containing capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, and homocapsaicin as active ingredients. The nasal rinse additive composition can further include vegetable glycerin, purified water, spearmint oil, lemongrass oil, sea salt, and/or ascorbic acid. The composition can be used to relieve and/or prevent pain, dryness, and/or inflammation associated with chronic and occasional nasal congestion.

An oral disintegrating tablet of dextromethorphan for treating the cold caused cough, nasal congestion and rhinorrhea is proportionally prepared from dextromethorphan, chlorphenamine, pseudoephedrine, beta-cyclodextrin or ion exchange resin, mannitol or lactose starch, and disintegrant through sieving, flavouring, mixing and die pressing.

The invention provides a rupatadine fumarate compound which has dual effects of antihistamine and antagonistic platelet activating factor (PAF). According to the research, allergy and inflammatory diseases are multi-factor complex processes caused by generation and release of various different media; histamine is the most inflammatory medium appearing in allergy early symptom, and the disease symptoms including sneezing, rhinocnesmus, tearing, running nose, skin itch, wheal and the like are mostly caused by histamine H1 receptor. And PAF also can cause bronchial constriction and increased permeability of the vessel, so that running nose, nasal congestion, wheal and itch are caused; meanwhile, the PAF is also a main cause of asthma. The antiallergic drug which is clinically used only has an antihistamine activity effect, but does not have a PAF antagonistic effect.

The invention relates to the technical field of anesthesia patient dry-mouth nursing, and discloses an anesthesia patient dry-mouth nursing device. The anesthesia patient dry-mouth nursing device includes a connection pipe, a nose plug sleeve is fixedly connected to the upper end of the connection pipe, an air storage box is fixedly connected to the lower end of the connection pipe, an airflow channel is fixedly connected to the interior of the connection pipe, a connection plate is fixedly connected to the left end of the airflow channel, and the side, away from the airflow channel, of the connection plate is fixedly connected with an air storage tank; and a push crank is movably connected to the bottom of the storage tank, and a gear is movably connected to the surface of the push crank.When swallowing saliva, a patient must jack up a tongue towards an oral palate, namely the tongue pushes the push crank to move close to the air storage tank, a spline meshes with the gear and movesupwards while rotating on the surface of a screw, then, a circular ring is driven to make contact with a flexible bag and extrude the flexible bag, when the flexible bag is extruded, a humidifying medical liquid inside the flexible bag is sprayed out from air holes, and therefore the effect can be achieved that when a mouth of the patient feels dry, the patient can independently control the humidifying medical liquid to spray out.